A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PMID- 28791836
DA  - 20170809
DCOM- 20170908
LR  - 20170908
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 26
IP  - 2
DP  - 2017 Mar-Apr
TI  - In vivo effects of curcumin and deferoxamine in experimental endometriosis.
PG  - 207-213
LID - 10.17219/acem/31186 [doi]
AB  - BACKGROUND: Endometriosis is one of the most common chronic gynecological
      diseases. OBJECTIVES: The aim of the study was to examine the effects of curcumin
      and/or deferoxamine on cell proliferation in a rat model of endometriosis.
      MATERIAL AND METHODS: Thirty female 12-week-old albino Wistar rats, weighing
      200-250 g, were used in this study. All the rats underwent ovariectomy and 0.1-mg
      beta-estradiol 17-valerate pellets were placed intraperitoneally. An experimental
      model of endometriosis was created in all the animals. To create the experimental
      model, an approximately 1-cm long section of the uterus was taken, primarily from
      the right horn of the uterus. Autologous fragments were then placed between the
      peritoneum and muscle. The animals were divided into 3 groups: Group A, treated
      only with the vehicle used for curcumin and deferoxamine; group B, treated with
      curcumin (100 mg/kg body weight); and group C, treated with deferoxamine +
      curcumin (100 mg/kg body weight). After biopsy samples were obtained, the
      sections were stained with hematoxylin and eosin. Immunostaining for
      cytokeratin-7 and proliferating cell nuclear antigen (PCNA) was performed. Blood 
      iron levels were measured using a Perkin Elmer AAnalyst 800 Atomic Absorption
      Spectrophotometer. RESULTS: The endometrial implant size increased in Group A,
      but treatment with curcumin (p = 0.01) and deferoxamine + curcumin (p = 0.007)
      reduced the implant size. In ectopic endometrial epithelial cells, there were
      significant decreases in PCNA immunoreactivity between groups A and B (p = 0.044)
      and between groups A and C (p = 0.033). CONCLUSIONS: Treatment with curcumin
      alone and/or in combination with deferoxamine contributed to a reduction in
      implant size and cell proliferation in a rat endometriosis model. Iron-chelating 
      agents may act in the same manner when used in women with endometriosis; however,
      further studies from different perspectives are still needed.
FAU - Kizilay, Gulnur
AU  - Kizilay G
AD  - Department of Histology and Embryology, Trakya University Faculty of Medicine,
      Edirne, Turkey.
FAU - Uz, Yesim Hulya
AU  - Uz YH
AD  - Department of Histology and Embryology, Trakya University Faculty of Medicine,
      Edirne, Turkey.
FAU - Seren, Gulay
AU  - Seren G
AD  - Department of Analytical Chemistry, Trakya University Faculty of Pharmacy,
      Edirne, Turkey.
FAU - Ulucam, Enis
AU  - Ulucam E
AD  - Department of Anatomy, Trakya University Faculty of Medicine, Edirne, Turkey.
FAU - Yilmaz, Ali
AU  - Yilmaz A
AD  - Department of Anatomy, Trakya University Faculty of Medicine, Edirne, Turkey.
FAU - Cukur, Ziya
AU  - Cukur Z
AD  - Experimental Animal Center, Trakya University, Edirne, Turkey.
FAU - Kayisli, Umit Ali
AU  - Kayisli UA
AD  - Department of Obstetrics and Gynecology, Morsani, College of Medicine, South
      Florida, USA.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical
JID - 101138582
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Keratin-7)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (Siderophores)
RN  - E1UOL152H7 (Iron)
RN  - IT942ZTH98 (Curcumin)
RN  - J06Y7MXW4D (Deferoxamine)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
MH  - Cell Proliferation/drug effects
MH  - Curcumin/*pharmacology
MH  - Deferoxamine/*pharmacology
MH  - *Disease Models, Animal
MH  - Drug Synergism
MH  - Endometriosis/blood/*drug therapy/metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Iron/blood
MH  - Keratin-7/metabolism
MH  - Ovariectomy
MH  - Proliferating Cell Nuclear Antigen/metabolism
MH  - Rats, Wistar
MH  - Siderophores/pharmacology
OT  - curcumin
OT  - deferoxamine
OT  - endometriosis
EDAT- 2017/08/10 06:00
MHDA- 2017/09/09 06:00
CRDT- 2017/08/10 06:00
PST - ppublish
SO  - Adv Clin Exp Med. 2017 Mar-Apr;26(2):207-213. doi: 10.17219/acem/31186.